Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)

被引：3
|
作者：
Yu, Evan Y. [1 ,2 ]
Piulats, Josep M. [3 ]
Gravis, Gwenaelle [4 ]
Fong, Peter C. C. [5 ,6 ]
Todenhoefer, Tilman [7 ]
Laguerre, Brigitte [8 ]
Arranz, Jose A. [9 ]
Oudard, Stephane [10 ]
Massard, Christophe [11 ,12 ]
Heinzelbecker, Julia [13 ,14 ]
Nordquist, Luke T. [15 ]
Carles, Joan [16 ]
Kolinsky, Michael P. [17 ,18 ]
Augustin, Marinela [19 ]
Gurney, Howard [20 ]
Tafreshi, Ali [21 ]
Li, Xin Tong [22 ]
Qiu, Ping [22 ]
Poehlein, Christian H. [22 ]
Schloss, Charles
de Bono, Johann S. [23 ,24 ]
机构：
[1] Univ Washington, Seattle, WA USA
[2] Fred Hutchinson Canc Ctr, Seattle, WA USA
[3] Catalan Inst Oncol, Barcelona, Spain
[4] Inst Paoli Calmettes, Marseille, France
[5] Auckland City Hosp, Auckland, New Zealand
[6] Univ Auckland, Auckland, New Zealand
[7] Studienpraxis Urol, Nurtingen, Germany
[8] Ctr Eugene Marquis, Rennes, France
[9] Gen Univ Hosp Gregorio Maranon, Madrid, Spain
[10] Univ Paris, Hop Europeen Georges Pompidou, Paris, France
[11] Gustave Roussy, Canc Campus, Villejuif, France
[12] Paris Saclay Univ, Villejuif, France
[13] Saarland Univ, Med Ctr, Homburg, Germany
[14] Saarland Univ, Fac Med, Homburg, Germany
[15] GU Res Network Urol Canc Ctr, Omaha, NE USA
[16] Vall Hebron Inst Oncol, Barcelona, Spain
[17] Cross Canc Inst, Edmonton, AB, Canada
[18] Univ Alberta, Edmonton, AB, Canada
[19] Paracelsus Med Univ, Nurnberg, Germany
[20] Macquarie Univ, Sydney, Australia
[21] Univ Wollongong, Wollongong, NSW, Australia
[22] Merck & Co Inc, Rahway, NJ USA
[23] Inst Canc Res, London, England
[24] Royal Marsden, London, England
来源：
EUROPEAN UROLOGY | 2023年 / 83卷 / 03期
关键词：
D O I：
10.1016/j.eururo.2022.11.025
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E87 / E87
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony M.
    Linch, Mark David
    Kolinsky, Michael Paul
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Kramer, Gero
    Shore, Neal D.
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [33] KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab plus vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Shore, Neal D.
    De Bono, Johann S.
    Kramer, Gero
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
    Sridhar, Srikala S.
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Rodriguez, Jose Maria M. Piulats
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
    Conter, Henry Jacob
    Shore, Neal D.
    Berry, William R.
    Fong, Peter C. C.
    Rodriguez, Jose Maria M. Piulats
    Appleman, Leonard Joseph
    Todenhoefer, Tilman
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] KEYNOTE-365 Cohort B: Pembrolizumab Plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer-New Data After an Additional 1 Year of Follow-Up
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 8 - 9
  • [37] Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine
    Lim, Emerson A.
    Petrylak, Daniel P.
    Peng, Weimin
    Kheoh, Thian
    Maul, Scott
    Smit, Johan W.
    Gonzalez, Martha D.
    De Porre, Peter
    NamPhuong Tran
    Nanus, David M.
    EUROPEAN UROLOGY, 2016, 70 (05) : 718 - 721
  • [38] KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
    Appleman, Leonard
    Todenhoefer, Tilman
    Berry, William
    Gurney, Howard
    Retz, Margitta
    Conter, Henry
    Laguerre, Brigitte
    Fong, Peter
    Ferrario, Cristiano
    Gravis, Gwenaelle
    Piulats, Josep
    Emmenegger, Urban
    Shore, Neal
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A374 - A374
  • [39] KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
    Appleman, Leonard Joseph
    Kolinsky, Michael Paul
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    De Bono, Johann S.
    Boegemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Massard, Christophe
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Linch, M.
    Ferrario, C.
    Stoeckle, M.
    Laguerre, B.
    Arija, J. A. Arranz
    Todenhofer, T.
    Fong, P. C.
    Rodriguez, J. M. Piulats
    Berry, W.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1178 - S1178
12345